Phebra acquires a stake in the capital of Flexipharm Austrading, a British company specializing in specialized hospitals
SYDNEY and BOURNE END, England, November 3, 2021 / PRNewswire / – Australia’s leading pharmaceutical group Phebra Holdings (“Phebra”) is pleased to announce that it has entered into a share purchase agreement with UK hospital-based pharmaceutical company Flexipharm Austrading Limited (” FAL ”).
Flexipharm Austrading, a private company founded in 2018 by an experienced expert in specialty pharmacy, Michael clark, focuses on supplying UK hospitals Better critical care drugs. Flexipharm Austrading has an existing license and distribution agreement with Phebra for the supply of products from Phebra’s critical care drug portfolio; To date, several products have been approved and successfully launched in the UK.
Andre Vlok, Managing Director Phebra, said: “We are delighted that Phebra has made this strategic investment in Flexipharm Austrading. This is a logical next step for Phebra, deepening a strong and fruitful collaboration built over the past 3 years. This strengthens Phebra’s access to the key UK market which is very important to our current and future critical care product pipeline.
“Our partnership will allow us to leverage FAL’s existing infrastructure under the expert guidance of Michael and advance our route to market in the UK and potentially, expand our international sales into wider European markets and selected. “
Michael clark, Founder and Managing Director of Flexipharm Austrading, said: “I created the company with the aim of providing British hospitals with Better critical care drugs; Phebra had a portfolio of products which we felt offered advantages over existing products and together we successfully launched them in the UK. But the work is only partly finished; I am delighted that Phebra is now a shareholder and look forward to deepening this relationship of delivering hospitals with a focus on improved or new versions of reference medicines and delivering tangible and transparent value to the NHS, healthcare professionals and independent hospitals. . ”
Phebra is an Australia-based specialty pharmaceutical group that develops, manufactures and markets essential medicines around the world.
At Phebra, we create essential medicines that save and improve lives.
About Flexipharm Austrading
Flexipharm Austrading’s vision is to become a UK-based specialty pharmaceutical company genuinely respected and trusted by NHS hospitals. It was founded in 2018 by Michael clark, founder and director of the board of directors of an experienced specialty pharmaceutical company. Flexipharm Austrading has a particular focus on the commercialization of established molecules integrated for use in hospitals when there are issues of continued security of supply; where the current presentation is not optimal for the needs of NHS staff; and where current presentations may contribute to medication errors. The company has a deep understanding of the conditions under which its medicines are used and establishes a lasting and meaningful dialogue with NHS staff involved in the use of these medicines. It works in partnership with Phebra Pty Ltd, an Australian pharmaceutical company that develops and manufactures injectable pharmaceuticals. For more information visit www.flexipharmaustrading.com.
SOURCE Flexipharm Austrading